- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02253836
Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir
A Single-Centre Open-Label Study in Healthy Adult Volunteers to Assess the Pharmacokinetic Interactions Between Steady-State TPV (500 mg) and Single-Dose and Steady-State Atazanavir (300 mg QD) in the Presence of Ritonavir (100 mg)
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male and female subjects between 18 and 60 years of age inclusive
- A Body Mass Index (BMI) between 18 and 29 kg/m2
- Signed informed consent prior to trial participation
- Ability to swallow multiple large capsules without difficulty
Acceptable laboratory values that indicate adequate baseline organ function at screening visit:
- Laboratory values are considered to be acceptable if the severity of any parameter is ≤ Grade 1, based on the Division of AIDS/AIDS Clinical Trials Group Grading Scale
- All abnormal laboratory values > Grade 1 are subject to approval by the trial clinical monitor
- Acceptable medical history, physical examination, and 12-lead ECG at screening
Willingness to abstain from the following starting 2 weeks prior to administration of any study medication and up until the end of the study:
- Grapefruit or grapefruit juice, Red wine, Seville oranges, St. John's Wort, and Milk Thistle
- Willingness to abstain from alcohol starting 3 days prior to administration of any study medication up to the end of the study
Willingness to abstain from the following starting 3 days prior to pharmacokinetic (PK) sampling:
- Garlic supplements and Methylxanthine containing foods or drinks (including coffee, tea, cola, energy drinks, chocolate, etc.)
- Willingness to abstain from over-the-counter herbal medications for the duration of the study
- Must be a non-smoker
- Willingness to abstain from vigorous physical exercise during intensive PK Days 1, 9, 23, 24 and 32
- Reasonable probability for completion of the study
Exclusion Criteria:
Female subjects of reproductive potential who:
- Have positive serum pregnancy test
- Have not been using a barrier method of contraception for at least 3 months prior to participation in the study
- Are not willing to use a reliable method of barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and 60 days after completion/termination of the trial
- Are breast-feeding
- Participation in another trial with an investigational medicine within 2 months prior to Day 0 of this study
- Use of any medication listed in the protocol within 30 days prior to Day 0 of this study
- Use of any pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month prior to Day 0 and for the duration of the study. Due to long half-life,subjects using of Depo-Provera within six months prior to Day 0 will be excluded from participation in this study
- Use of hormone replacement therapy within 1 month prior to Day 0 and anytime during the study
- Administration of antibiotics within 15 days prior to Day 0 and anytime during the study
History of acute illness within 60 days prior to Day 0
o Subjects will be excluded for acute illnesses that occurred more than 60 days prior to Day 0 if, in the opinion of the investigator, the subject does not qualify as a healthy volunteer
- Have serological evidence of hepatitis B or C virus
- Have serological evidence of exposure to HIV
- Alcohol or substance abuse within 1 year prior to screening or during the study
- Blood or plasma donations within 30 days prior to Day 0 or during the study
- Subjects with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering Tipranavir, Ritonavir or Atazanavir to the subject
- Subjects with pre-existing heart conduction abnormalities
- Subjects who have taken (within 7 days prior to Day 0) any over-the-counter or prescription medication that, in the opinion of the investigator in consultation with the clinical monitor, might interfere with absorption, distribution, or metabolism of the study medications
- Known hypersensitivity to sulphonamide class of drugs
- Inability to adhere to the protocol
- Cautions or warnings in the Ritonavir and Atazanavir package insert which, in the opinion of the investigator, constitute grounds for subject exclusion
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: TAZ/RTV - TPV/RTV - TPV/RTV+TAZ
Days 1-9: single dose TAZ/RTV Days 16-23: morning and evening dose TPV/RTV Days 24-32: TPV/RTV + TAZ |
TPV
RTV
TAZ
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Maximum plasma concentration
Prazo: up to day 33
|
up to day 33
|
Drug concentration in plasma at 12 hr after administration for Tipranavir (TPV) and Ritonavir (RTV)
Prazo: 12 hours after drug administration
|
12 hours after drug administration
|
Drug concentration in plasma at 24 hr after administration for Atazanavir (TAZ)
Prazo: 24 hours after drug administration
|
24 hours after drug administration
|
Area under plasma concentration time curve from 0-12 hours (AUC0-12h) for TPV and RTV
Prazo: up to 12 hours after drug administration
|
up to 12 hours after drug administration
|
AUC0-24h for TAZ
Prazo: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
---|---|
Time from dosing to the maximum concentration
Prazo: up to day 33
|
up to day 33
|
Elimination half-life
Prazo: up to day 33
|
up to day 33
|
Oral clearance
Prazo: up to day 33
|
up to day 33
|
Volume of distribution
Prazo: up to day 33
|
up to day 33
|
Number of patients with adverse events
Prazo: up to day 33
|
up to day 33
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Anti-Infecciosos
- Antivirais
- Inibidores Enzimáticos
- Agentes anti-HIV
- Antirretrovirais
- Inibidores de Protease
- Inibidores do citocromo P-450 CYP3A
- Inibidores da enzima citocromo P-450
- Inibidores da Protease do HIV
- Inibidores de Protease Viral
- Ritonavir
- Tipranavir
- Sulfato de Atazanavir
Outros números de identificação do estudo
- 1182.61
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Tipranavir
-
Boehringer IngelheimConcluído
-
Boehringer IngelheimConcluído
-
Boehringer IngelheimConcluídoInfecções por HIVEstados Unidos, Porto Rico
-
Boehringer IngelheimAprovado para comercializaçãoInfecções por HIVBélgica, Brasil, Canadá, Dinamarca, El Salvador, Grécia, Itália, Portugal, Espanha
-
Boehringer IngelheimConcluídoInfecções por HIVEstados Unidos, Argentina, Austrália, Áustria, Bélgica, Brasil, Canadá, Dinamarca, França, Alemanha, Grécia, Itália, México, Holanda, Portugal, Espanha, Suíça, Reino Unido
-
Boehringer IngelheimRetirado
-
Boehringer IngelheimAprovado para comercializaçãoInfecções por HIVEstados Unidos, Austrália, Bélgica, Dinamarca, França, Grécia, Irlanda, Itália, Portugal, África do Sul, Suíça, Reino Unido
-
Boehringer IngelheimConcluído
-
Boehringer IngelheimRescindido
-
Boehringer IngelheimRescindidoInfecções por HIVEstados Unidos, Argentina, Brasil, França, Alemanha, Itália, Espanha